Eli Lilly to invest another $27 billion in U.S. manufacturing

Published 26/02/2025, 19:56
© Reuters

Investing.com -- On Wednesday, Eli Lilly (NYSE:LLY) announced plans to invest an additional $27 billion in U.S. pharmaceutical manufacturing, bringing its total domestic capital expansion commitments to over $50 billion since 2020. 

The company revealed it will build four new manufacturing sites this year, creating more than 13,000 jobs across manufacturing and construction.

Lilly’s investment marks the largest pharmaceutical manufacturing expansion in U.S. history. The company said three of the planned sites will focus on active pharmaceutical ingredient (API) production, reinforcing domestic small molecule chemical synthesis capabilities. 

The fourth site is expected to expand its global parenteral manufacturing network for injectable therapies.

“Lilly’s optimism about the potential of our pipeline across cardiometabolic health, oncology, immunology, and neuroscience drives our unprecedented commitment to domestic manufacturing,” said David Ricks, Lilly chair and CEO. “This bold move reflects our commitment to stay ahead of anticipated demand for safe, high-quality, FDA-approved medicines.”

The four new facilities are expected to create over 3,000 highly skilled jobs, including positions for engineers, scientists, and lab technicians. An additional 10,000 construction jobs will be generated during development.

Lilly emphasized that the 2017 Tax Cuts and Jobs Act played a foundational role in enabling its domestic expansion. “It is essential that these policies are extended this year,” Ricks added, noting that investment in American manufacturing will drive economic growth and innovation.

Following the news, analysts at Deutsche Bank (ETR:DBKGn) said they believe the Street “anticipated LLY expanding its CapEx for the large Diabesity demand.” 

However, “today’s announcement of four new US manufacturing facilities is an incremental positive that helps to somewhat mitigate President Trump implementing Pharma tariffs,” wrote the bank.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.